Inventor · disambiguated record
Lars Thim
Also filed as: THIM LARS
18 granted patents·37 pending applications·505 citations·filing 1981–2018
95Inventor score
Top patents by PatentIndex Score
55 records- 0192US7411039B2GLP-2 compounds, formulations, and uses thereofNOVO NORDISK AS·Filed 2003·Granted Aug 12, 2008·69 cites·31 claims
- 0289US5912229AUse of a pharmaceutical composition comprising an appetite-suppressing peptideNOVO NORDISK AS·Filed 1997·Granted Jun 15, 1999·112 cites·17 claims
- 0388US5783416AHuman spasmolytic polypeptide in glycosylated formNOVO NORDISK AS·Filed 1994·Granted Jul 21, 1998·46 cites·17 claims
- 0487US4916212ADNA-sequence encoding biosynthetic insulin precursors and process for preparing the insulin precursors and human insulinNOVO INDUSTRI AS·Filed 1985·Granted Apr 10, 1990·75 cites·32 claims
- 0584US5705482APharmaceutical formulationNOVO NORDISK AS·Filed 1995·Granted Jan 6, 1998·70 cites·12 claims
- 0678US4826763AProcess for preparing glucagon or fragments or derivatives thereof in yeastNOVO INDUSTRI AS·Filed 1986·Granted May 2, 1989·26 cites·2 claims
- 0773US2008274964A1Human Spasmolytic Polypeptide in Glycosylated FormNOVO NORDISK AS·Filed 2008·Application pending·0 cites
- 0870US9150848B2Conjugated factor VIII moleculesNOVO NORDISK AS·Filed 2014·Granted Oct 6, 2015·1 cites·12 claims
- 0969US8536126B2Conjugated factor VIII moleculesNOVO NORDISK AS·Filed 2013·Granted Sep 17, 2013·1 cites·7 claims
- 1067US2009011461A1Human Spasmolytic Polypeptide in Glycosylated FormNOVO NORDISK AS·Filed 2008·Application pending·0 cites
- 1166US4370317APancreatic spasmolytic polypeptideNOVO INDUSTRI AS·Filed 1981·Granted Jan 25, 1983·27 cites·11 claims
- 1265US2006211605A1Mucosal repair by TFF dimer peptidesNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 1365US2006019881A1Human spasmolytic polypeptide in glycosylated formTHIM LARS·Filed 2005·Application pending·0 cites
- 1464US2009149387A1Use of GLP-1 PeptidesNOVO NORDISK AS·Filed 2009·Application pending·0 cites
- 1564US2005287640A1Human spasmolytic polypeptide in glycosylated formTHIM LARS·Filed 2005·Application pending·0 cites
- 1664US2010184644A1Mucosal repair by tff dimer peptidesTHIM LARS·Filed 2009·Application pending·0 cites
- 1763US4816441APeptides and compositionsNOVO INDUSTRI AS·Filed 1986·Granted Mar 28, 1989·17 cites·22 claims
- 1863US2008045450A1GLP-2 DerivativesKNUDSEN LISELOTTE B·Filed 2006·Application pending·0 cites
- 1960US5175113AModified β2 -microglobulinNOVO NORDISK AS·Filed 1990·Granted Dec 29, 1992·21 cites·13 claims
- 2059US2007161568A1Use of GLP-1 peptidesNOVO NORDISK AS·Filed 2007·Application pending·0 cites
- 2157US9125890B2Compounds suitable for treatment of haemophiliaNOVO NORDISK AS·Filed 2013·Granted Sep 8, 2015·0 cites·20 claims
- 2257US2013189239A1Conjugated Factor VIII MoleculesBOLT GERT·Filed 2009·Application pending·0 cites
- 2356US2003077696A1Human spamolytic polypeptide in glycosylated formFiled 2000·Application pending·0 cites
- 2456US2018179262A1Compounds Suitable for Treatment of HaemophiliaNOVO NORDISK AS·Filed 2018·Application pending·0 cites
- 2553US2006111278A1TFF peptidesTHIM LARS·Filed 2004·Application pending·0 cites
- 2653US2015080309A1Compounds Suitable for Treatment of HaemophiliaNOVA NORDISK AS·Filed 2013·Application pending·0 cites
- 2752US2006293221A1Mucosal repair by TFF2 peptidesNOVO NORDISK AS·Filed 2006·Application pending·0 cites
- 2852US2004127418A1GLP-2 derivativesFiled 2003·Application pending·0 cites
- 2952US2011028391A1Use of GLP-1 PeptidesNOVO NORDISK AS·Filed 2010·Application pending·0 cites
- 3052US2003232754A1Use of GLP-1 peptidesFiled 2003·Application pending·0 cites
- 3151US2003215431A1Management of mucosal viscosity by TFF monomer peptidesFiled 2003·Application pending·0 cites
- 3251US2010113363A1Use of GLP-1 PeptidesNOVO NORDISK AS·Filed 2010·Application pending·0 cites
- 3351US2016264645A1Stabilized Factor VIII VariantsNOVO NORDISK AS·Filed 2016·Application pending·0 cites
- 3450US2003153496A1Mucosal repair by TFF dimer peptidesFiled 2002·Application pending·0 cites
- 3549US2016222086A1Conjugated Factor VIII MoleculesNOVO NORDISK AS·Filed 2015·Application pending·0 cites
- 3649US2007060609A1Identification and Use of Growth Hormone Secretagogue Receptor Type 1A AntagonistsANDERSON MAIBRITT B·Filed 2006·Application pending·0 cites
- 3749US2006039862A1Identification and use of growth hormone secretagogue receptor type 1A antagonistsNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 3848US5552385APharmaceutical formulationNOVO NORDISK AS·Filed 1995·Granted Sep 3, 1996·10 cites·15 claims
- 3948US5051371AModified β2 -microglobulinNOVO NORDISK AS·Filed 1987·Granted Sep 24, 1991·14 cites·5 claims
- 4047US6022858APharmaceutical formulation of human-growth hormone pretreated with zinc saltNOVO NORDISK AS·Filed 1998·Granted Feb 8, 2000·11 cites·9 claims
- 4147US2015045303A1Pharmaceutical Composition Suitable for Treatment of HaemophiliaNOVO NORDISK AS·Filed 2013·Application pending·0 cites
- 4247US2002025933A1GLP-2 derivativesFiled 2001·Application pending·0 cites
- 4347US2003032585A1Mucosal repair by TFF2 peptidesFiled 2002·Application pending·0 cites
- 4446US2004063636A1Use of compounds for the regulation of food intakeFiled 2003·Application pending·0 cites
- 4546US2016318991A1Compounds Suitable for Treatment of HaemophiliaNOVO NORDISK AS·Filed 2016·Application pending·0 cites
- 4645US2013183280A1Stabilized factor viii variantsOESTERGAARD HENRIK·Filed 2011·Application pending·0 cites
- 4744US2002151472A1TFF peptidesFiled 2001·Application pending·0 cites
- 4843US2006105948A1GLP-2 derivativesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 4942US8399620B2Purification of factor VIII using a mixed-mode or multimodal resinBANG SUSANNE·Filed 2008·Granted Mar 19, 2013·0 cites·16 claims
- 5042US2016207977A1Compounds Suitable for Treatment of HaemophiliaNOVO NORDISK AS·Filed 2014·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lars Thim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →